ClinicalTrials.gg
CompletedNCT03597100PROSPECTUpdated Oct 12, 2023Results posted

Prospective Study for Symptomatic Relief of ET With Cala Therapy

An interventional study of Cala TWO in Essential Tremor, sponsored by Cala Health, Inc.. Completed at 32 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by Cala Health, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
263
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Essential Tremor with a site in United States — 40 open to participants now, 46 under way, 1 of them phase 3. Essential Tremor · United States.

Enrollment
6th of 104
263 · median 30
Started
2018
with 4 others
No phase
60 of 146
22 open now
Registered
76th of 146
by date
Lead sponsor
5 of 146
Cala Health, Inc.

Among the 146 studies in Essential Tremor with a site in United States, this one is the 6th largest by enrollment of the 104 interventional ones that give a count, is one of 5 that started in 2018, is one of 60 with no phase, and was the 76th registered.

Essential Tremor

272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.

Browse Essential Tremor studies →

Open to participants now

40 of the 146 studies in Essential Tremor with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Essential Tremor with a site in United States, or all of them as a file.
02

Study summary

Prospective, multi-center, single-arm, non-significant risk study designed to evaluate the Cala TWO device. Subjects will be screened for eligibility and fitted with a Cala TWO device. Subjects will wear the device at home for a period of 3 months, during which they will be asked to stimulate their dominant hand twice a day. The stimulation amplitude will be based on each subject's stimulation threshold. Subjects will have in clinic assessments at enrollment, month 1 and 3.

03

Conditions studied

  • Essential Tremor

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be ≥22 years of age
  • Competent and willing to provide written, to participate in the study
  • A diagnosis of essential tremor as confirmed from clinical history and examination by a movement disorder neurologist
  • A tremor severity score of 2 or above in the dominant hand/arm as measured by any one of the TETRAS upper limb items and a minimum subset score of 6 across all upper limb items
  • Significant disability due to essential tremor (Bain \& Findley score of 3 or above in any one of the upper limb items and a minimum subset score of 8 across all upper limb items)
  • Stable dose of tremor medications, if applicable, for 30 days prior to study entry
  • Stable dose of antidepressant medications, if applicable, for 90 days prior to study entry
  • Willing to comply with study protocol requirements including:

    • remaining on a stable dosage of tremor and antidepressant medications, if applicable, during the duration of the study
    • no significant alcohol or caffeine consumption within 8 hours prior to study visits
    • no usage of the Cala TWO device within 8 hours prior to study visits

Exclusion criteria

Exclusion Criteria:

  • Moderate to severe ethanol dependence as defined by the criteria outlined in the (score of 4 or higher)
  • Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator, or implanted metal in the wrist to be stimulated
  • Previous thalamotomy procedure, including stereotactic thalamotomy, gamma knife radiosurgical thalamotomy, and focused ultrasound for the treatment of tremor
  • Suspected or diagnosed epilepsy or other seizure disorder
  • Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
  • Peripheral neuropathy affecting the tested upper extremity
  • Presence of any other neurodegenerative disease like Parkinson-plus syndromes suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease.
  • Anyone suspected to have the diagnosis of idiopathic Parkinson's disease (PD). This includes excluding anyone with the presence of parkinsonian features including bradykinesia rigidity, or postural instability. Subjects who exhibit only mild resting tremor but no other symptoms or signs of PD may be included.
  • Botulinum toxin injection for hand tremor within 6 months prior to study enrollment
  • Are participating or have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor
  • Significant alcohol or caffeine consumption within 8 hours prior to study enrollment, which may confound the results of the study, where significant caffeine is considered more than 95 mg (equivalent to a cup of coffee), and significant alcohol is considered more than 14 g (equivalent to 5 oz of wine, 12 oz of beer, or 1.5 oz of distilled spirits).
  • Subjects unable to communicate with the investigator and staff
  • Any health condition that in the investigator's opinion should preclude participation in this study
  • Pregnancy or anticipated pregnancy during the course of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    Cala TWO

    Two 40-minute stimulation sessions daily, separated by at least two hours

    Device: Cala TWO

Interventions

  • DeviceCala TWO

    Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves

06

What researchers measure

Primary outcomes

  1. TRG (Tremor Research Group) Essential Tremor Rating Assessment Scale (TETRAS) Subset Score

    Tremor Research Group (TRG) Essential Tremor Rating Assessment Scale (TETRAS) subset score: TETRAS subset score relevant to the stimulated upper limb. The subset score is the sum of 6 rated tasks. Each task is rated 0 to 4, where a higher score indicates more severe tremor. Minimum subset score = 0; Maximum subset score = 24.

    Time frame: Baseline to 3-months

  2. Bain & Findley Activities of Daily Living (ADL) Scale Subset Score

    Bain \& Findley ADL subset score relevant to the stimulated upper limb. The subset score is the sum of 8 rated tasks. Each task is rated 1 to 4, where a higher score indicates more severe tremor. Minimum subset score = 8; Maximum subset score = 32.

    Time frame: Baseline to 3-months

Secondary outcomes

  1. Kinematic Measurements, as Collected With the Device During Postural Holds, Change From Pre-stimulation to Post-stimulation Across Sessions

    Subjects will be prompted to perform a postural hold task before and after each stimulation session. During this task, the device will record kinematic data using on-board motion sensors to objectively assess if there are any changes in tremor level. The change in each patient's pre- and post-stimulation tremor power was defined as the median change over all valid stimulation sessions. Sample mean and standard deviations were computed using the median change value from all patients.

    Time frame: Average change in tremor power over 3-month study period

07

Results

Posted Oct 12, 2023

Participant flow

Participant flow — Overall Study
MilestoneCala TWO
Started263
Completed205
Not completed58

Outcome measures

PrimaryTRG (Tremor Research Group) Essential Tremor Rating Assessment Scale (TETRAS) Subset Score

Tremor Research Group (TRG) Essential Tremor Rating Assessment Scale (TETRAS) subset score: TETRAS subset score relevant to the stimulated upper limb. The subset score is the sum of 6 rated tasks. Each task is rated 0 to 4, where a higher score indicates more severe tremor. Minimum subset score = 0; Maximum subset score = 24.

Time frame:
Baseline to 3-months
Reported as:
Mean · score on a scale
TRG (Tremor Research Group) Essential Tremor Rating Assessment Scale (TETRAS) Subset Score
score on a scaleCala TWO
Baseline12.6 ± 2.7
Final Visit9.8 ± 3.5
Change-2.8 ± 2.8
PrimaryBain & Findley Activities of Daily Living (ADL) Scale Subset Score

Bain \& Findley ADL subset score relevant to the stimulated upper limb. The subset score is the sum of 8 rated tasks. Each task is rated 1 to 4, where a higher score indicates more severe tremor. Minimum subset score = 8; Maximum subset score = 32.

Time frame:
Baseline to 3-months
Reported as:
Mean · score on a scale
Bain & Findley Activities of Daily Living (ADL) Scale Subset Score
score on a scaleCala TWO
Baseline18.4 ± 3.8
Final Visit13.4 ± 4.4
Change-4.98 ± 4.3
SecondaryKinematic Measurements, as Collected With the Device During Postural Holds, Change From Pre-stimulation to Post-stimulation Across Sessions

Subjects will be prompted to perform a postural hold task before and after each stimulation session. During this task, the device will record kinematic data using on-board motion sensors to objectively assess if there are any changes in tremor level. The change in each patient's pre- and post-stimulation tremor power was defined as the median change over all valid stimulation sessions. Sample mean and standard deviations were computed using the median change value from all patients.

Time frame:
Average change in tremor power over 3-month study period
Reported as:
Mean · (m/s^2)^2
Kinematic Measurements, as Collected With the Device During Postural Holds, Change From Pre-stimulation to Post-stimulation Across Sessions
(m/s^2)^2Cala TWO
Kinematic Measurements, as Collected With the Device During Postural Holds, Change From Pre-stimulation to Post-stimulation Across Sessions-0.8 ± 3.7

Adverse events

Collected over Up to 3 months since baseline testing. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cala TWO1/263 (0.4%)5/263 (1.9%)47/263 (17.9%)
Most frequent serious events
Most frequent serious events
EventCala TWO
Initial or prolonged hospitalizationGeneral disorders5/263
Most frequent other events
Most frequent other events
EventCala TWO
Significant and persistent skin irritationSkin and subcutaneous tissue disorders14/263
Sore/LesionSkin and subcutaneous tissue disorders10/263
Significant discomfortSkin and subcutaneous tissue disorders6/263
Electrical burnsSkin and subcutaneous tissue disorders6/263
Minor Skin IrritationSkin and subcutaneous tissue disorders6/263
Other isolated eventsSkin and subcutaneous tissue disorders5/263
Electric shock sensation while using deviceSkin and subcutaneous tissue disorders3/263
Worsening of tremorNervous system disorders2/263

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cala TWO
Mean69.6 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Cala TWO
Female137
Male126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cala TWO
Hispanic or Latino7
Not Hispanic or Latino253
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cala TWO
American Indian or Alaska Native0
Asian11
Native Hawaiian or Other Pacific Islander0
Black or African American7
White237
More than one race3
Unknown or Not Reported5
Region of Enrollment
Region of Enrollment(participants)Cala TWO
United States263
08

Study locations

32 sites
  • Barrow Neurological Institute (Dignity Health)
    Phoenix, Arizona 85013, United States
  • USC
    Los Angeles, California 90033, United States
  • Parkinson's Institute and Clinical Center
    Mountain View, California 94040, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Pacific Neuroscience Institute
    Santa Monica, California 90404, United States
  • Rocky Mountain Movement Disorders Center
    Denver, Colorado 80113, United States
  • Hospital for Special Care
    New Britain, Connecticut 06053, United States
  • Medstar Gerogetown Health Institute
    Georgetown, District of Columbia 20007, United States
  • Parkinson's Center
    Boca Raton, Florida 33486, United States
  • USF
    Tampa, Florida 33612, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Kaiser Mid-Atlantic Group
    Largo, Maryland 20774, United States
  • Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Health System
    West Bloomfield, Michigan 48322, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Advanced Neurology Specialists
    Great Falls, Montana 95405, United States
  • Parkinson's Disease and Movement Disorders Center of Long Island
    Long Island City, New York 10017, United States
  • Mount Sinai & Beth Isreal
    New York, New York 10003, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Wake Forest
    Raleigh, North Carolina 27157, United States
  • River Hills Neuroscience
    Cincinnati, Ohio 45255, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University Of Pennsylvania Medicine
    Philadelphia, Pennsylvania 19104, United States
  • Jefferson University
    Philadelphia, Pennsylvania 19144, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Texas Movement Disorder Specialist
    Georgetown, Texas 78628, United States
  • Houston Methodist
    Houston, Texas 77030, United States
  • Central Texas Neurology Consultants
    Round Rock, Texas 78681, United States
  • Swedish
    Bellevue, Washington 98004, United States
  • EvergreenHealth Medical Center
    Kirkland, Washington 98034, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in May 2019, 5 months.

Results were first posted in Oct 2023, 4 years 4 months after primary completion.

Of 95 interventional studies with no phase under Essential Tremor, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 93. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2018
First posted
Jul 24, 2018
StartActual
Dec 14, 2018
Primary completionActual
May 29, 2019
CompletionActual
May 29, 2019
Results first posted
Oct 12, 2023
Last update
Oct 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03597100
Lead sponsor
Cala Health, Inc.
Responsible party
Sponsor
First posted
Jul 24, 2018
Start date
Dec 14, 2018
Primary completion
May 29, 2019
Completion
May 29, 2019
Results posted
Oct 12, 2023
Last update
Oct 12, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion